Price Alert

Immunocore (IMCR)

NASDAQ: IMCR · Real-Time Price · USD

33.20

0.20 (0.61%)

At close: Aug 14, 2025, 3:59 PM

33.06

-0.42%

After-hours: Aug 14, 2025, 04:10 PM EDT

0.61% (1D)

Bid	30.3
Market Cap	1.67B
Revenue (ttm)	356.14M
Net Income (ttm)	-20.31M
EPS (ttm)	-0.41
PE Ratio (ttm)	-80.98
Forward PE	-36.24
Analyst	Buy

Ask	34.81
Volume	355,609
Avg. Volume (20D)	400,816
Open	32.91
Previous Close	33.00
Day's Range	32.09 - 33.28
52-Week Range	23.15 - 39.33
Beta	0.78

About IMCR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMCR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMCR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Immunocore has released their quartely earnings on Aug 7, 2025:

Revenue of $97.96M exceeds estimates by $5.38M, with 29.93% YoY growth.

EPS of -0.2 exceeds estimates by 0.01, with 13.04% YoY growth.

Next Earnings Release

Immunocore is scheduled to release its earnings on Nov 5, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+6.63%

Immunocore Holdings shares are trading higher afte... Unlock content with Pro Subscription

News

6 days ago · seekingalpha.com

Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript

Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robert...

1 week ago · fool.com

Immunocore (IMCR) Q2 Revenue Jumps 30%

Immunocore Plc (IMCR 0.06%), a biotechnology company specializing in T cell receptor therapies, reported its second quarter 2025 results on August 7, 2025. The main headline was a solid revenue increa...

1 week ago · zacks.com

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Immunocore (IMCR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare...

3 weeks ago · zacks.com

Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The consensus price target hints at a 72.3% upside potential for Immunocore (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...

1 month ago · zacks.com

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli...

2 months ago · zacks.com

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the pos...

2 months ago · zacks.com

Is it a Good Idea to Invest in Immunocore Stock Right Now?

IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.

3 months ago · zacks.com

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...